Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $530 thousand.

For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.

Earnings